Literature DB >> 31702744

Statement on Seasonal Influenza Vaccine for 2012-2013: Appendix I: New Evidence Review for Children 24 to 59 Months of Age: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

.   

Abstract

Entities:  

Year:  2012        PMID： 31702744      PMCID： PMC6802449          DOI： 10.14745/ccdr.v38i00a02a

Source DB:  PubMed          Journal:  Can Commun Dis Rep        ISSN： 1188-4169


× No keyword cloud information.
  64 in total

1.  Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children.

Authors:  K M Zangwill; J Droge; P Mendelman; S M Marcy; S Partridge; C Y Chiu; J Jing; S J Chang; I Cho; J I Ward
Journal:  Pediatr Infect Dis J       Date:  2001-08       Impact factor: 2.129

2.  Effectiveness of inactivated influenza vaccine in children less than 5 years of age over multiple influenza seasons: a case-control study.

Authors:  Avni Y Joshi; Vivek N Iyer; Jennifer L St Sauver; Robert M Jacobson; Thomas G Boyce
Journal:  Vaccine       Date:  2009-05-31       Impact factor: 3.641

3.  Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials.

Authors:  Janelle Rhorer; Christopher S Ambrose; Stephanie Dickinson; Holli Hamilton; Napoleon A Oleka; Frank J Malinoski; Janet Wittes
Journal:  Vaccine       Date:  2008-12-16       Impact factor: 3.641

4.  A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children.

Authors:  Robert F Breiman; W Abdullah Brooks; Doli Goswami; Rosanna Lagos; Charissa Borja-Tabora; Claudio F Lanata; Jaime A Cèspedes Londoño; Lucy Chai See Lum; Ruth Rappaport; Ahmad Razmpour; Robert E Walker; William C Gruber; Bruce D Forrest
Journal:  Vaccine       Date:  2009-07-17       Impact factor: 3.641

5.  The underrecognized burden of influenza in young children.

Authors:  Katherine A Poehling; Kathryn M Edwards; Geoffrey A Weinberg; Peter Szilagyi; Mary Allen Staat; Marika K Iwane; Carolyn B Bridges; Carlos G Grijalva; Yuwei Zhu; David I Bernstein; Guillermo Herrera; Dean Erdman; Caroline B Hall; Ranee Seither; Marie R Griffin
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245

6.  Prophylactic effect of inactivated influenza vaccine on young children.

Authors:  Taro Maeda; Yukihiro Shintani; Hajime Miyamoto; Hiroyuki Kawagoe; Kanako Nakano; Atsusi Nishiyama; Yoshiyasu Yamada
Journal:  Pediatr Int       Date:  2002-02       Impact factor: 1.524

7.  Influenza Β/Victoria antigen induces strong recall of Β/Yamagata but lower Β/Victoria response in children primed with two doses of Β/Yamagata.

Authors:  Danuta M Skowronski; Travis S Hottes; Gaston De Serres; Brian J Ward; Naveed Z Janjua; Suzana Sabaiduc; Tracy Chan; Martin Petric
Journal:  Pediatr Infect Dis J       Date:  2011-10       Impact factor: 2.129

8.  Influenza A and B virus infections in children.

Authors:  Ville Peltola; Thedi Ziegler; Olli Ruuskanen
Journal:  Clin Infect Dis       Date:  2003-01-20       Impact factor: 9.079

9.  Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children.

Authors:  Manjusha J Gaglani; Pedro A Piedra; Gayla B Herschler; Melissa E Griffith; Claudia A Kozinetz; Mark W Riggs; Charles Fewlass; M Elizabeth Halloran; Ira M Longini; W Paul Glezen
Journal:  Arch Pediatr Adolesc Med       Date:  2004-01

Review 10.  The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults.

Authors:  Christopher S Ambrose; Myron J Levin; Robert B Belshe
Journal:  Influenza Other Respir Viruses       Date:  2010-11-19       Impact factor: 4.380
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.